Merck claims Vytorin beats Zocor
Company says a study shows the cholesterol drug, which joins Zocor and Zetia, is better than Zocor alone.
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) - A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.

Vytorin reduced LDL, or "bad" cholesterol, by 52.5 percent, compared to 38.0 percent for Zocor, said Merck (unchanged at $34.76, Research). The results of the study were presented at an American College of Cardiology conference in Atlanta on Monday.

The study results might help Merck keep from losing patients to a cheaper, generic form of Zocor, when the blockbuster loses patent protection in June. Vytorin sales totaled $2.4 billion in 2005. Zocor sales totaled $4.4 billion in 2005.

The study also showed that Vytorin reduced C-reactive protein, considered a risk for heart disease, by 31.0 percent with Vytorin, compared to a reduction of 14.3 percent with Zocor, Merck said.

Vytorin is a combination of Zetia, a Schering-Plough (unchanged at $18.05, Research) drug that stops cholesterol absorption into the liver and intestine, and Zocor, which cuts cholesterol.

To read more about the impending patent loss to Zocor, click hereTop of page

YOUR E-MAIL ALERTS
Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.